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Obesity, long considered a condition characterized by the deposition of inert fat, is now recognized as a chronic and systemic
inﬂammatorydisease,whereadiposetissueplaysacrucialendocrinerolethroughtheproductionofnumerousbioactivemolecules,
collectively known as adipokines. These molecules regulate carbohydrate and lipid metabolism, immune function and blood
coagulability, and may serve as blood markers of cardiometabolic risk. Local inﬂammatory loops operate in adipose tissue as a
consequence of nutrient overload, and crosstalk among its cellular constituents-adipocytes, endothelial and immune cells-results
in the elaboration of inﬂammatory mediators. These mediators promote important systemic eﬀects that can result in insulin
resistance,dysmetabolismandcardiovasculardisease.Theunderstandingthatinﬂammationplaysacriticalroleinthepathogenesis
of obesity-derived disorders has led to therapeutic approaches that target diﬀerent points of the inﬂammatory network induced by
obesity.
1.Introduction
Atherothrombosis is the basis of most coronary, peripheral,
and cerebral arterial disease and is a critical health burden
and major cause of death worldwide [1]. Despite the unde-
niable importance of cardiovascular disease in morbidity
and mortality in most regions of the world, control of risk
factors and advances in the treatment of atherothrombosis
havesigniﬁcantlyreducedage-adjustedcardiovascularevents
inUSAandWesternEurope.However,allthisprogressinthe
waragainstcardiovasculardiseasehasbeenthreatenedbythe
dramatic increase in the prevalence of obesity, an important
risk factor for both atherogenesis and increased coagulability
[1].
The signiﬁcant advance of the obesity epidemic world-
wide and the association between atherothrombosis and
obesity have attracted great interest from the scientiﬁc
community, contributing importantly to increase the under-
standing of the pathophysiology of excess adiposity. Indeed,
several concepts related to obesity pathophysiology have
changed in the last 2 decades [2]. The hypothesis of
obesity as a low-grade chronic and systemic inﬂammatory
disease gradually replaced the idea of a mere lipid deposit
disease characterized by inert adipose tissue and passive
a c c u m u l a t i o no ff a ti nt h ec o n t e x to fw e i g h tg a i n[ 2, 3].
Several research groups demonstrated that adipose tissue
of obese animals and humans produces increased amounts
of inﬂammatory mediators and presents higher number
of inﬂammatory cells compared to adipose tissue of lean
controls [2, 3]. This recently recognized endocrine role of
adipose tissue likely provides a crucial mechanistic link
between obesity and atherothrombosis.
2. Inﬂammatory Mechanismsof Obesity
2.1. The Local Inﬂammatory Network in Adipose Tissue. The
ﬁrst clues supporting the involvement of inﬂammation in
obesity came to light almost half a century ago, including a
report that described increased plasma levels of ﬁbrinogen in
obese patients [4]. However, the inﬂammatory view of obe-
sity started attracting interest in the 1990s, particularly after
the demonstration of enhanced expression of tumor necrosis
factor-alpha (TNF-α) in adipose tissue of obese rodents and
the amelioration of insulin resistance after neutralization of2 International Journal of Inﬂammation
this potent cytokine [5, 6]. Since the publication of these
reports, several other groups demonstrated the production
and secretion of multiple cytokines, chemokines, hormones,
and other inﬂammatory mediators by adipose tissue, col-
lectively referred to as adipokines, culminating with the
recognition of adipose tissue as one of the greatest endocrine
organs in the body [7]. Besides the aforementioned cytokine
TNF-α, macrophage chemoattractant protein-1 (MCP-1),
plasminogenactivatorinhibitor-1(PAI-1),interleukin-6(IL-
6), leptin, and adiponectin are remarkable examples of
adipokines diﬀerentially expressed by obese adipose tissue,
with potentially important roles in the pathophysiology of
obesity, either locally or systemically [7–11].
Adipocytes constitute the major cell type of adipose
tissue, being a major source of several bioactive products
secreted by this tissue. Indeed, they are responsible for the
production of several adipokines, among which adiponectin
andleptinarelikelyexclusivelyelaboratedinadipocytes.Pio-
neer work published in 2003 demonstrated that adipocytes
are not alone and that macrophages also accumulate in
adipose tissue of obese animals (Table 1 and Figure 1), coin-
ciding with increased expression of inﬂammatory markers
and preceding a signiﬁcant increase in circulating insulin
levels [12, 13]. Since then, extensive work has supported the
involvement of macrophages in the inﬂammatory network
of adipose tissue. Studies on the contribution of MCP-1
and its receptor, chemokine (C-C motif) receptor 2 (CCR2),
both important mediators of macrophage recruitment to
sites of inﬂammation (Figure 1), demonstrated reduced
macrophage accumulation in adipose tissue of diet-induced
obese mice deﬁcient in either of those genes [22, 23]. These
knockout animals exhibit decreased insulin resistance and
hepatic steatosis, suggesting that adipose tissue macrophage
inﬂux contributes to the local and systemic metabolic eﬀects
of obesity [22, 23]. However, the role of the MCP-1/CCR2
duo in obesity-induced inﬂammation remains incompletely
understood, as not all studies found the inﬂuence of MCP-1
deﬁciency relevant to macrophage accumulation in adipose
tissue or insulin sensitivity [24, 25].
Macrophages are not all equal in the inﬂamed adipose
tissue, according to diﬀerential phenotypic patterns and
chemokine receptor usage [26]. Whereas the so-called resi-
dent macrophages, the dominant subtype in lean fat tissue,
predominantly express markers of alternative activation or
M2 (such as mannose receptor C type I), the inﬁltrative
macrophages, widely present within the obese adipose tissue,
are characterized by their enhanced expression of classic
activation or M1 markers, such as TNF-α and inducible NO
synthase (iNOS) [14]. Interestingly, adipose tissue-derived
macrophages from obese CCR2-deﬁcient mice present sig-
niﬁcantly less expression of M1 markers than their wild-type
counterparts, with M2 markers at levels comparable to those
from lean mice [14]. Thus, although CCR2-deﬁcient animals
have a less prominent subset of inﬁltrative macrophages
within their adipose tissue, their population of adipose
tissue-resident macrophages remains intact, suggesting the
usage of distinct chemokine receptors by diﬀerent subsets
of macrophages and local operation of various chemotactic
systems [14].
In the last ﬁve years, other inﬂammatory cell types have
also been gathering attention in the pathophysiology of
obesity. T cells, although less numerous than macrophages,
also accumulate in adipose tissue of obese mice (Table 1 and
Figure 1). We and others showed the presence of both T
cell subpopulations, CD4+ and CD8+, in fat tissue [15–18].
Nishimura and colleagues reported that mice fed a high-
fat diet have an increased number of CD8 cells in adipose
tissue and that depletion of these cells reduced macrophage
inﬁltration and adipose tissue inﬂammation and improved
systemic insulin resistance [18].
The classic Th1 cytokine interferon-gamma (IFN-γ) also
ﬁgures importantly in the inﬂammatory circuit that operates
in obese adipose tissue (Figure 1). In one study, high-fat diet
promoted a progressive IFN-γ bias among adipose tissue-
derived T cells in mice [27]. Furthermore, IFN-γ or IFN-
γ-receptor deﬁciencies lower adipose tissue expression of
inﬂammatory genes and ameliorate metabolic parameters
in obese animals [16]. In humans, a positive association of
CD3+cells and IFN-γ mRNA expression in adipose tissue
with waist circumference in a cohort of patients with type
2 diabetes mellitus suggests the involvement of the Th1 arm
of adaptive immunity in obesity-related metabolic disorders
[17].
Whereas proinﬂammatory T cells appear enriched in
obese adipose tissue, the pool of anti-inﬂammatory T cells,
CD4+ Foxp3+ T regulatory (Treg) cells, decreases in fat
tissue of obese animals compared to their lean counterparts
[19]( Table 1). Using loss-of-function and gain-of-function
approaches, Feuerer and colleagues revealed that Treg cells
inﬂuencetheinﬂammatorystateofadiposetissueandinsulin
resistance. The higher number of Treg cells in lean fat
tissue may be one important factor to restrain inﬂammation
and keep local homeostasis [19, 27]. In humans, Th1 cells
expressing the transcription factor Tbet outnumber Foxp3+
T cells with a ratio of approximately 12:1 in visceral adipose
tissue of obese individuals, compared to 6:1 in lean ones
[27].
Recent studies highlighted potential roles for other
immune cells, such as mast cells and natural killer T (NKT)
cells, in adipose tissue inﬂammation [20, 21]( Table 1).
Genetic deﬁciency of mast cells or their pharmacological
stabilization in diet-induced obese mice reduce weight gain,
adipose tissue, and systemic inﬂammation and improve
glucose metabolism and energy expenditure [20]. Mice
lacking NKT also present less adipose tissue inﬂammation
and glucose intolerance than wild-type control animals
when fed a high-fat diet [21] .Ar e c e n ts t u d yh a sr e p o r t e d
an important role of eosinophils in the maintenance of
metabolic homeostasis [28]. These cells are major producers
of IL-4 that contribute to sustain alternatively activated
macrophages in adipose tissue [28].
2.2. Systemic Inﬂammatory Loops. The global endocrine
proﬁle of adipose tissue appears to reﬂect the interactions
among its paracrine loops. In other words, local crosstalks
involving adipocytes, endothelial cells, and immune cells
result in the production of a wide repertoire of bioactive
substances that can act in a paracrine fashion, furtherInternational Journal of Inﬂammation 3
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Figure 1: Adipose tissue inﬂammation in obesity. Whereas lean adipose tissue contains a population of resident inﬂammatory cells (1)
and secretes various active substances, the obese adipose tissue (2) accumulates higher numbers of macrophages and T cells, producing
copious amounts of inﬂammatory mediators, such as monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6), and less
adiponectin (3). In the context of nutrient surplus and hypoxia, expanding adipocytes present endoplasmic reticulum (ER) stress (3),
important trigger of inﬂammatory kinases, such as JNK and IKK, which can ultimately inhibit insulin signaling (further detail in the
text) and activate inﬂammatory cascades and the production of inﬂammatory mediators. Existing evidence suggests that higher production
of chemokines, such as MCP-1, within the obese adipose tissue could enhance local macrophage accumulation (4). Once in the tissue,
monocyte-derived macrophages can be a fundamental source of tumor necrosis factor-alpha (TNFα), among other mediators. Cytokines
like TNFα and other stimuli can cause further activation of inﬂammatory kinases (5). Several studies have demonstrated that T cells
also accumulate in adipose tissue in the obese state (6). Interferon-gamma (IFNγ), a typical T-helper 1 cytokine, likely regulates local
expression of TNFα, MCP-1, and other inﬂammatory mediators, suggesting a role for adaptive immunity in obesity pathophysiology.
The spillover of adipokines, such as IL-6, into the circulation can also promote important systemic eﬀects (7), such as increased
production of liver-derived acute-phase inﬂammatory mediators and coagulation-related factors, most of them likely correlated with
atherothrombosis.4 International Journal of Inﬂammation
Table 1: Inﬂammatory cell types in adipose tissue.
Inﬂammatory cells in
adipose tissue
network of obesity
Comments
Macrophages
Accumulate in obese versus lean AT. Presence correlated with ↑ expression of inﬂammatory mediators in AT
and metabolic disturbances [12, 13].
Inﬁltrative macrophages and M1 markers predominate over resident macrophages and M2 markers in obese AT
[14].
Tc e l l s
Fewer than macrophages, they also accumulate in obese versus lean AT [15–17].
Depletion of CD8 lymphocytes from DIO-mice ↓ macrophage accumulation in AT and ↓ systemic IR [18].
CD4+ Foxp3+ T regulatory cells (Treg) decrease in AT of obese versus lean mice. Treg cells may keep
homeostasis and limit inﬂammation in lean AT [19].
Mast cells Genetic deﬁciency of mast cells or their pharmacological stabilization in DIO-mice ↓ weight gain, AT, and
systemic inﬂammation, and improve glucose metabolism and energy expenditure [20].
NKT cells DIO-mice lacking NKT cells present less AT inﬂammation and glucose intolerance than wild-type control
animals [21].
AT: adipose tissue; DIO-mice: diet-induced obese mice.
amplifying inﬂammation within the adipose tissue [29]. At
thesametime,thespilloverofadipokinesintothecirculation
can also promote important systemic eﬀects, and speciﬁc
mediators such as adiponectin, leptin, plasminogen activator
inhibitor-1 (PAI-1), and IL-6 may even serve as blood
markers of cardiometabolic risk.
2.2.1. Adiponectin. The most abundant and one of the most
extensively studied adipokines is adiponectin. Unlike most
other adipokines, adiponectin plasma levels are lower in
obese than in nonobese individuals [30]. It circulates in
the plasma at levels of 3–30mg/mL and forms three major
oligomeric complexes with distinct biological functions:
trimer, hexamer, and high-molecular-mass form, the latter
likely being the most bioactive form in vascular cells
(reviewed in [31]). There is also a bioactive proteolytic
product of adiponectin that includes its C1q-like globular
domain, which circulates at low concentration in plasma
[32]. The adiponectin receptors, AdipoR1 and AdipoR2,
activate signaling molecules such as AMP-activated protein
kinase (AMPK), peroxisome-proliferator-activated recep-
tor (PPAR)-α, and p38 mitogen-activated protein kinase
(MAPK) [33]. Targeted disruption of AdipoR1 and Adi-
poR2simultaneouslyabrogatesadiponectinbinding,causing
insulin resistance and glucose intolerance [34].
Numerous experimental studies support the idea that
adiponectin has antidiabetic properties [31]. Adiponectin-
deﬁcient (APN−/−) mice exhibited late clearance of free
fatty acids from plasma and diet-induced insulin resis-
tance [35], whereas adiponectin delivery via adenovirus in
those knockout animals improved insulin sensitivity [35].
In another study, ob/ob mice overexpressing adiponectin
showed improved glucose tolerance and reduced triglyceride
levels compared to their nontransgenic ob/ob littermates in
spite of being morbidly obese [36]. Nevertheless, the inter-
pretation of these results is often diﬃcult from a mechanistic
standpoint, because diﬀerent studies used distinct forms of
the recombinant protein [32, 37].
Vast literature also suggests anti-inﬂammatory and
antiatherogenic properties of adiponectin. Studies have
shown anti-inﬂammatory eﬀects of adiponectin on most
cells involved in atherogenesis, including endothelial
cells and macrophages [38, 39]. Physiological levels of
adiponectin attenuate the attachment of monocytes to
the endothelium in culture by reducing TNF-α-induced
expression of adhesion molecules [38]. Pretreatment of
human macrophages with adiponectin attenuates lipopol-
ysaccharide- (LPS-) induced expression of TNF-α,a n do f
a trio of T-lymphocyte chemoattractants associated with
atherogenesis: interferon- (IFN-) inducible protein 10 (IP-
10/CXCL10), IFN-inducible T-cell alpha chemoattractant
(I-TAC/CXCL11), and monokine induced by IFN-gamma
(MIG/CXCL9) [39]. Whereas the anti-inﬂammatory
mechanisms elicited by adiponectin are not completely
understood, recent work from our laboratory shed some
light on this arena. We demonstrated that pretreatment
of human macrophages with adiponectin inhibits phos-
phorylation of nuclear factor κB inhibitor (IκB), c-Jun
N-terminal kinase (JNK), and p38 MAPK induced by either
LPS or TNF-α as well as signal transducer and activation
of transcription 3 (STAT3) phosphorylation induced by
IL-6 [40]. Interestingly, treatment of human macrophages
with adiponectin alone induced sustained phosphorylation
of IκB, JNK, p38, and STAT3 but prevented further
activation of these signaling molecules upon addition of
pro-inﬂammatory agonists [40]. These ﬁndings and others
from additional studies suggest that adiponectin may induce
some degree of inﬂammatory activation that likely mediates
tolerance to further treatment with pro-inﬂammatory
stimuli [40–42].
Several animal studies have conﬁrmed the anti-inﬂam-
matory and antiatherogenic properties of adiponectin. Ade-
novirus-mediated delivery of adiponectin to apolipoprotein-
E-deﬁcient (ApoE−/−) mice, an atherosclerotic murine
model, reduced plaque formation in the aortic sinus [43].
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with ApoE−/− mice also had less atherosclerotic burden than
ApoE−/− control animals, despite similar plasma glucose
and lipid levels44. Additionally, APN−/− mice exhibited a 5-
fold increase in leukocyte adhesion in the microcirculation,
in association with decreased NO levels and augmented
expression of adhesion molecules in the endothelium [44].
Yet, a recent study that used APN−/− mice and transgenic
mice with chronically elevated adiponectin levels crossed to
ApoE−/− or LDLR−/− mice found no correlation between
adiponectin levels and atheroma development [45].
Multiple clinical studies have correlated hypoadiponect-
inemia with insulin resistance and type II diabetes mellitus
in various populations [46, 47]. Recently, a meta-analysis
of prospective studies that involved 14,598 subjects demon-
stratedthathigheradiponectinconcentrationsassociatewith
lower risk of type II diabetes [48] .Ar e c e n ts t u d yt h a t
compared metabolic parameters in insulin-resistant versus
insulin-sensitive obese individuals demonstrated that the
strongest predictors of insulin sensitivity were macrophage
inﬁltration in adipose tissue and circulating levels of
adiponectin [49]. Genetic studies have also provided a link
betweenadiponectinandmetabolicdisorders.Geneticmuta-
tions that likely reduce adiponectin plasma concentrations
[50, 51] and adiponectin multimerization [52] associate
closely with type II diabetes. These ﬁndings, although
correlational in nature and thus not proving direct causal-
ity, support a primary role for adiponectin in preventing
metabolic disease in humans.
Abundant data from several epidemiological studies have
also reported an inverse correlation between adiponectin
plasma levels and incidence of hypertension [53], dyslipi-
demia [54, 55], and cardiovascular disease [38, 56, 57].
Patients with coronary artery disease (CAD) have lower
adiponectinemia than controls [38]. Similarly, men with
both type II diabetes and CAD have lower circulating
levels of adiponectin than patients with diabetes without
CAD [56]. Another study showed a 2-fold increase in
the prevalence of CAD among male patients with low
plasmaconcentrationsofadiponectin,independentofclassic
risk factors [57] .P r o s p e c t i v ed a t ah a v ea l s od e m o n s t r a t e d
that high plasma adiponectin concentrations associate with
lower risk of myocardial infarction in healthy men [58],
and decreased CAD risk in diabetic men [59]. However,
there are prospective studies that have not observed a
correlation between adiponectinemia and risk of future
CAD [60, 61]. Furthermore, a large prospective study and
meta-analysis found a weak association between CAD and
plasma adiponectin levels [62]. Intriguingly, two secondary
prevention studies associated adiponectin with an increased
risk of recurrent cardiovascular events [63, 64]. These
conﬂicting studies indicate that further prospective analyses
of various populations are still necessary to examine whether
adiponectinemia can independently predict cardiovascular
disease.
2.2.2. Leptin. Leptin, a 16kDa hormone product of the
ob gene [65], is predominantly released by adipocytes
[66] to control body weight centrally through its cognate
receptor in the hypothalamus [67]. Leptin circulates in the
plasma at levels proportional to total body adiposity [68]
and immediate nutritional state. In fed states, leptin levels
increaseand,viaacentralactioninthebrain,inhibitappetite
andstimulatethyroid-mediatedthermogenesisandfattyacid
oxidation. In a fasting situation, leptin levels fall, and thus
appetite increases, and thermogenesis becomes limited.
Leptin deﬁciency associates with increased appetite and
marked obesity in mice and humans, a scenario completely
abrogated by treatment with recombinant leptin [69]. Inter-
estingly, human obesity only rarely associates with leptin
deﬁciencyorleptinreceptormutations.Inthecommonform
of obesity, leptin concentrations are actually increased in
proportion to body adiposity [70], and the response of body
weight to recombinant leptin is modest [71], deﬁning a state
of leptin resistance [72].
In addition to its role in energy homeostasis, leptin
participates in other energy-demanding physiological pro-
c e s s e ss u c ha sr e p r o d u c t i o n[ 73], hematopoiesis [74], and
angiogenesis [75]. Several studies have also shown that
leptin has an important immunomodulatory role [76]. In
monocytes or macrophages, it increases phagocytic function
and proinﬂammatory cytokine production [77]. In poly-
morphonuclear cells of healthy subjects, it stimulates the
production of reactive oxygen species [78] and chemotaxis
[79]. Leptin is also involved in processes of cell development,
proliferation, activation, and cytotoxicity of NK cells [80]. In
adaptive immunity, leptin polarizes Th cytokine production
toward a proinﬂammatory phenotype (Th1) [76].
Leptin signaling occurs typically via Janus tyrosine
kinases (JAKs) and STATs. After binding to its functional
receptor (ObRb), which is expressed not only in hypotha-
lamus, but also in all cell types of innate and adaptive
immunity [76, 81, 82], leptin recruits JAKs and activates the
receptor, which serves as a docking site for adaptors such
as STATs [83]. STATs translocate to the nucleus and induce
gene expression. Several studies in human peripheral blood
mononuclear cells have demonstrated that although the
JAK-2-STAT-3 pathway constitutes an important pathway
mediating leptin’s function on immune cells, there are other
pathways involved in this activity, such as the MAPK, the
insulin receptor substrate 1, and the phosphatidyl-inositol
3 -kinase pathways [84].
2.2.3. Plasminogen Activator Inhibitor (PAI-1). Obesity and
metabolic syndrome promote a hyperthrombotic state
through distinct pathways that involve hypoﬁbrinolysis,
hypercoagulability, and platelet activation [85]. One of the
most remarkable abnormalities of the haemostatic system
in the context of obesity and metabolic syndrome is the
increased circulating concentrations of PAI-1 [86, 87], which
seems particularly associated with higher production of this
factor by the fatty liver, ectopic adipose tissues, and dysfunc-
tional endothelium. PAI-1 correlates with all components of
the insulin resistance syndrome, and weight loss associates
with a signiﬁcant decrease in PAI-1 levels [88].
PAI-1 is a serpin that regulates both tissue plasminogen
activator (tPA) and urokinase plasminogen activator (uPA),
likely representing the principal physiological inhibitor of
plasminogen activation [89]. Thus, the increase in PAI-16 International Journal of Inﬂammation
levels observed in obesity and metabolic syndrome impairs
ﬁbrinolysis and may inﬂuence the risk of atherothrombosis.
In addition to hypoﬁbrinolysis, obesity and metabolic
syndrome appear associated with enhanced platelet activ-
ity [87]. Moreover, higher concentrations of vitamin K-
dependent coagulation factors and ﬁbrinogen may also
accompany excess adiposity, at least partially due to its
inﬂammatory component [86]. Endothelial dysfunction,
likely an important element in obesity, may also contribute
to the thrombotic diathesis observed in this condition
[87], through increased expression of proinﬂammatory
and haemostatic products such as microparticles and von
Willebrand factor.
2.2.4. Interleukin-6 (IL-6). IL-6 is an inﬂammatory cytokine
with distinct pathophysiologic roles in humans. It stimulates
the hypothalamic-pituitary-adrenal axis, being under neg-
ative control by glucocorticoids and positive regulation by
catecholamines [90]. IL-6 is a potent inducer of the acute-
phasereaction[90]thatcirculatesathighlevelsduringstress,
inﬂammatory and infectious diseases. In mice, the metabolic
roleofIL-6isnotfullyunderstood.Micegeneticallydeﬁcient
in IL-6 develop mature-onset obesity, partly reversed with
IL-6 administration, and abnormalities in carbohydrate and
lipid metabolism [91]. On the other hand, mice chronically
exposed to IL-6 develop hepatic insulin resistance [92].
In either case though, IL-6 is likely a critical metabolic
modulator.
Several immune cell types, including but not limited
to monocytes, constitute typical sources of IL-6 [93].
In the last decades, the study of adipose tissue as an
endocrine organ unraveled its abundant production of IL-
6. Indeed, subcutaneous adipose tissue appears to release
approximately 25% of circulating IL-6 in humans [94].
The obese state associates with increased secretion of IL-
6 and, therefore, higher hepatic release of acute-phase
reactants, C-reactive protein (CRP) likely being the major
one [95]. A large bulk of evidence, including experimental
and cross-sectional data, suggests that both IL-6 and CRP
correlate with hyperglycemia, insulin resistance, and type 2
d i a b e t e sm e ll i t u s[ 96–100]. A prospective study found strong
correlation between baseline IL-6 and CRP levels and risk of
developing type 2 diabetes mellitus [101]. After multivariate
analysis and adjustment for adiposity measurements, there
was signiﬁcant attenuation of the association between IL-6
and risk of diabetes, but CRP persisted as an independent
predictor of incident diabetes [101].
Excess adiposity, particularly central adiposity, also asso-
ciates with elevated levels of CRP. Indeed, besides the higher
CRP levels in obese than in nonobese individuals, there is
a positive correlation between CRP and waist-to-hip ratio
(a measurement of visceral obesity) even after adjustment
for BMI [102]. CRP, a liver-derived pentraxin, also correlates
well with other risk factors and increased cardiovascular risk
in the absence of acute inﬂammation. It has emerged as
one of the most promising biomarkers for future cardiovas-
cular events since 1997, when the Physicians Health Study
demonstrated a strong and independent correlation between
systemic levels of CRP and future occurrence of myocardial
infarction and stroke in apparently healthy men [103]. After
this work, several other prospective studies corroborated
the CRP capacity of predicting cardiovascular events, even
beyond traditional risk factors [104–110]. Besides the evi-
dence in primary prevention, several studies also suggested
that CRP levels predict eﬃciently new cardiovascular events
in individuals who already had a myocardial infarction [111,
112]. CRP levels also seem to correlate with cerebrovascular
events [113] and development of peripheral vascular disease
[114].
Despite the large bulk of evidence on the CRP prediction
capacity, the utility of this biomarker in risk stratiﬁcation
beyond traditional risk factors is not consensual, with
opponents arguing that it only has a modest ability of
stratifying the risk beyond conventional scores according to
the C statistic [115, 116].
A recent meta-analysis including individual records of
160,309 people without a history of vascular disease from
54 long-term prospective studies showed that log(e)C R P
concentration was linearly associated with several conven-
tional risk factors and inﬂammatory markers, and nearly
log-linearly with the risk of ischemic vascular disease and
nonvascular mortality [117]. However, the risk ratios for
coronary heart disease, ischemic stroke, vascular mortality,
and nonvascular mortality per 1-SD higher log(e)C R P
concentration decreased when adjusted for age and sex
and even further for conventional risk factors [117]. These
results suggest that a great proportion of the vascular
risk associated with CRP depends on its correlation with
traditional risk factors. On the other hand, CRP still kept its
ability of predicting vascular events (and even non-vascular
mortality) despite the adjustment for several conventional
risk factors [117]. Interestingly, after further adjustment
for other markers of inﬂammation, such as ﬁbrinogen, the
relativeriskdeclinedsigniﬁcantly,suggestingthatCRPmight
be indeed an eﬃcient marker of systemic inﬂammation but
probably not a causal factor of atherothrombosis per se.A
genetic study on the polymorphisms in the CRP gene also
suggests a noncausal link between CRP levels and the risk of
ischemicvasculardisease[118].Inthiswork,geneticvariants
associated with lifelong elevations in circulating CRP, and
therefore, with a theoretically predicted increase in the risk
of ischemic vascular disease, failed to show the expected risk
[118].
Research has also tested the utility of CRP beyond risk
stratiﬁcation. JUPITER (justiﬁcation for the use of statins
in primary prevention: an intervention trial evaluating
rosuvastatin) for example, tested the value of CRP as a
therapeutic guide for the initiation of statins [119]. This
study found a signiﬁcant reduction in cardiovascular events
among individuals with low LDL-cholesterol levels (LDL
<130mg/dL), but high CRP levels (CRP >2mg/L) receiving
Rosuvastatin 20mg per day compared to placebo [119]. The
noninclusion of a group of people with low LDL-cholesterol
and low CRP levels and the early interruption of the study
ﬁgure among its limitations and most frequent critics.
Multiple studies have also showed that several other
adipokines, such as resistin, retinoid binding protein 4
(RBP4), visfatin, and omentin, present varied potentialInternational Journal of Inﬂammation 7
eﬀects on glucose homeostasis. Extensive reviews on these
bioactive mediators exist elsewhere [120, 121].
3. PotentialLinksbetweenInﬂammationand
InsulinResistance
Ample literature supports that insulin resistance precedes
the development of overt hyperglycemia and type 2 diabetes
[122]. Genetic burden and acquired conditions, including
obesity as one of the most relevant, may play a role in
the origin of insulin resistance [122]. While pancreatic β-
cells properly respond to insulin resistance with substantial
secretion of insulin, glucose metabolism stays equilibrated.
Once the pancreas fails in overcoming insulin resistance with
more insulin release, hyperglycemia, and eventually diabetes
mellitus ensue.
In adipose tissue and skeletal muscle, insulin promotes
cellular glucose uptake through a system of intracellular
substrates [123]. Upon insulin binding to its receptor at
the cell surface, members of the insulin receptor substrate
(IRS) family become tyrosine phosphorylated. This process
leads to downstream signaling which triggers translocation
ofGLUT-4fromintracellularstorestothecellularmembrane
and, therefore, glucose transport into the cell [124]. The
phosphorylation of particular serine residues of IRS-1 may
instead abrogate the association between IRS-1 and the
insulin receptor, impairing insulin signaling [125]. Inﬂam-
matory mediators such as TNF-α or elevated levels of free
fatty acids may activate serine kinases, such as c-Jun NH2-
terminal kinase (JNK) and IκB kinase (IKK) (Figure 1),
which phosphorylate serine residues of IRS-1 and disrupt
insulin signaling [126–129]. Both JNK and IKK, which
are members of two major pro-inﬂammatory cascades, are
likely activated in insulin-resistant states, and thus provide
potential connections between inﬂammation and insulin
resistance [127, 130, 131].
Experimental research with JNK-1-deﬁcient mice
showed substantial reduction of IRS-1 serine phosphory-
lation and amelioration of insulin sensitivity [127]. Be-
sides serine phosphorylation of IRS-1, IKK-β can also in-
ﬂuence insulin function through phosphorylation of the
NFκB inhibitor (IκB), leading to activation of NFκB. The
stimulation of this potent inﬂammatory pathway culminates
with further production of several inﬂammatory substances
including TNF-α, which can maintain and potentiate
inﬂammatory activation [132]. Experiments involving ro-
dents with targeted disruption of IKK-β demonstrated signi-
ﬁcant attenuation of insulin resistance [130]. There are
also other kinases, such as mammalian target of rapamycin
(mTOR), protein kinase R (PKR), and protein kinase θ
(PKθ) that can induce inhibitory phosphorylation of IRS-1,
and thus contribute to nutrient and inﬂammation-related
disruption of insulin signaling [133].
Although obesity-associated inﬂammation probably ini-
tiates in adipocytes, where nutrient overload is ﬁrst sensed,
adipose tissue is not the only organ characterized by local
inﬂammation,norisitsolelyresponsibleforsystemicinﬂam-
mation and glucose metabolism abnormalities in obesity
[3]. The liver, as another major metabolic site in the
body, also participates importantly in the systemic inﬂam-
matory networks of obesity by experiencing activation of
inﬂammatory pathways within its local cells [3]. The liver
contains a resident population of macrophage-like cells, the
Kupﬀer cells, which can secrete inﬂammatory mediators
upon activation. However, unlike adipose tissue, the liver
does not accumulate macrophages or other immune cells in
the context of obesity. Animal studies involving liver-speciﬁc
gain-of-function or loss-of-function of IKK-β increased our
understanding on the role of obese liver in inﬂammation-
related insulin resistance [132, 134]. Hepatocyte-speciﬁc
deletionofIKK-βprotectstheliverbutnotmuscleoradipose
tissue of obese mice from insulin resistance [134]. On the
other hand, transgenic mice with constitutively active IKK-
β in hepatocytes display increased hepatic production of
inﬂammatory cytokines, severe hepatic insulin resistance,
and moderate systemic insulin resistance [132]. Intriguingly,
speciﬁc deletion of JNK-1 in hepatocytes deteriorated glu-
cose homeostasis in mice [135], whereas administration of
a cell-permeable JNK-inhibitory peptide had the opposite
eﬀect, improving insulin sensitivity and glucose tolerance in
diabetic mice [136]. In summary, although adipose tissue
may be the organ where energy surplus exerts its ﬁrst eﬀects,
presenting a pivotal role in the inﬂammatory and metabolic
derangements of obesity, other metabolic organs, such as
the liver, also seem to participate in this loop although in a
somehow more localized manner.
4. The Originof the Inﬂammatory
Response inObesity
Despite the large bulk of data available on the local and
systemic inﬂammatory networks operating in obesity, the
precise triggers of inﬂammation in this condition remain
unidentiﬁed. However, several recent studies have brought
potential answers to fundamental questions in this fas-
cinating area of research. A reasonable hypothesis posits
that nutrient overload in metabolic cells such as adipocytes
induces intracellular stress which results in activation of
inﬂammatory cascades [3, 137]( Figure 1). The endoplasmic
reticulum (ER), an organelle specialized in protein folding,
maturation, storage, and transport, senses nutrient levels in
the cell. Under conditions of cellular stress induced by nutri-
ent surplus, misfolded or unfolded proteins accumulate in
the ER and activate the so-called unfolded protein response
(UPR) pathway [138]. The UPR functioning depends
essentially on three main ER sensors: PKR-like eukaryotic
initiationfactor2αkinase(PERK),inositolrequiringenzyme
1 (IRE-1), and activating transcription factor 6 (ATF-6)
[139]. Once activated, the UPR leads to increased activity of
the kinases JNK and IKK-β, serine-phosphorylation of IRS-
1, and activation of the NFκB pathway, leading to enhanced
proinﬂammatory cytokine expression and impaired insulin
signaling [3, 140–142].
The ER also responds to other conditions of cellular
stress, such as hypoxia, another element of obese adipose
tissue [124]. As obesity evolves and enlargement of adipose
tissue ensues, the expanding adipocytes get relatively
hypoxic. Regions of microhypoxia within the adipose tissue8 International Journal of Inﬂammation
also exhibit increased activation of inﬂammatory pathways
[143, 144].
It is also possible that, in excess, nutrients can themselves
directly activate immune pathogen-sensors in the cell such
as toll-like receptors (TLRs), which likely respond to excess
fatty acids and may contribute to insulin resistance [145].
TLR4 deﬁciency improves insulin sensitivity in high-fat diet-
induced obese mice [145, 146]. PKR, another pathogen-
sensor in the cell, is likely activated in mice during lipid
infusion and in obesity [147] and, as discussed above, is also
able to activate JNK and IKK and disrupt insulin signaling.
5. Obesity,Inﬂammation, and
CardiovascularDisease
There are numerous potential mechanisms by which in-
creased adiposity may induce atherothrombosis and cardio-
vascular disease [85]. Obesity, predominantly visceral, often
associates with other morbid conditions, such as insulin
resistance, glucose and lipid abnormalities, and hyperten-
sion, each one an independent cardiovascular risk factor
per se. Moreover, the inﬂammatory state that characterizes
obesity is likely an important connection between this
conditionandtheothercardiovascularriskfactors,andatthe
same time, a possible direct link to atherothrombosis [85].
Indeed, as aforementioned, excess adiposity often correlates
with abnormal production of several mediators which
often associate with cardiovascular events. The adipokine
imbalance characterizing obesity, including low levels of
adiponectin, high levels of leptin, inﬂammatory mediators
(IL-6 and TNF-α) and antiﬁbrinolytic factors (PAI-1) may
induce oxidative stress and endothelial dysfunction, initial
steps of atherogenesis. Moreover, the insulin-resistant state
of obesity frequently involves high circulating levels of non-
esteriﬁed fatty acids, which cause lipotoxicity, and therefore
further oxidative stress and endothelial dysfunction. As
described above, numerous studies also support an inde-
pendent association between circulating levels of CRP, an
inﬂammatory marker potently induced by IL-6 and TNF-α
(in excess in the obesity state), and cardiovascular events.
6. InsightsintoAnti-Inﬂammatory Therapies
All the evidence linking obesity-related metabolic disorders
to inﬂammation raises the question whether modulation
of inﬂammatory pathways would have a beneﬁcial impact
on metabolism. Several studies have targeted inﬂammation
at diﬀerent points of the inﬂammatory network of obesity,
ranging from inhibition of circulating cytokines to suppres-
sion of intracellular inﬂammatory cascades and ER stress.
The approval of anti-TNF-α compounds for clinical use
in patients with speciﬁc inﬂammatory conditions motivated
studies with these reagents in obese and insulin-resistant
subjects. These trials have yielded conﬂicting results on
the improvement of insulin sensitivity by TNF-α blockers,
such as etanercept [148, 149], and ﬁnal conclusions warrant
further studies.
Another promising anti-inﬂammatory approach in obe-
sity and insulin-resistant states targets kinases and intra-
cellular inﬂammatory pathways. Salsalates, nonacetylated
members of the group of salicylates, appear to modulate
inﬂammation through suppression of IKK action [29].
Clinical studies have shown decreased inﬂammation and
improved metabolism, including glucose and lipid parame-
ters, in diabetic subjects under therapy with salsalates [150].
Studies involving JNK antagonists, available for mice but still
lacking for human treatment, also yielded positive results in
glucose metabolism [136].
Since ER stress may represent one major source of
inﬂammatory signals within the cell, it provides a potential
therapeutic target for modulation of inﬂammation and
metabolic derangements. Indeed, attenuation of ER stress
through use of chemical chaperones restores glucose home-
ostasisinamousemodeloftype2diabetes[151].Inhumans,
studies are still limited, but already reveal positive metabolic
results [152].
Thiazolidinediones (TZDs) are peroxisome proliferator-
activated receptor-γ (PPARγ) agonists, which possess signif-
icant anti-inﬂammatory eﬀects and insulin-sensitizing prop-
erties[153].PPARγ isanucleartranscriptionfactor,member
of the nuclear-receptor superfamily, with important regula-
tory eﬀects on inﬂammatory processes. As a synthetic ligand
ofPPARγ,TZDsmayactviarepressionofinﬂammatorygene
promoters [154]. They can also exert PPARγ-independent
stimulation of glucocorticoid receptors [155]. By activating
PPARγ, these compounds can also regulate genes related
to adipocyte diﬀerentiation, lipid metabolism, and glucose
uptake, each of which can contribute to their beneﬁcial
metabolic eﬀects. However, changes in ﬂuid balance and in
myocardial function and predisposition to fractures render
the therapeutic use of TZDs, more speciﬁcally rosiglitazone,
challenging in speciﬁc groups of patients, particularly in
patients with heart failure or increased cardiovascular risk
[156–158].
The use of nutrients with anti-inﬂammatory properties
may constitute another promising weapon against obesity.
Mice receiving high fat diet supplemented with omega-3
polyunsaturated fatty acids (n-3 PUFAs) had reduced adi-
pose tissue inﬂammation and improved insulin sensitivity
[159]. In type 2 diabetic individuals, supplementation with
omega-3 fatty acids has beneﬁcial eﬀects on serum triglyc-
erides, HDL-cholesterol, lipid peroxidation, and antioxidant
enzymes, which may lead to reduced rate of occurrence of
vascular complications in those patients [160]. In diabetic
women, high consumption of ﬁsh and long-chain omega-
3 fatty acids supplementation associated with decreased
cardiovascular risk [161].
Finally,cell-basedimmunomodulationofobesityinﬂam-
mation has recently attracted attention although it is still
incipient. Several animal studies, including some discussed
above, demonstrated signiﬁcant metabolic beneﬁts as a
consequenceofdepletionorstimulationofspeciﬁccellpools.
Whereas deﬁciency or inhibition of CD11c-positive cells
[162], CD8 T cells [18], mast cells [20] and NKT cells
[21] improves metabolic parameters, an increase in the pool
of CD4+ Foxp3+ T cells following CD3-speciﬁc antibodyInternational Journal of Inﬂammation 9
treatment likely produce similar beneﬁcial metabolic eﬀects
[27].
7. Conclusions
Far beyond a mere inert lipid storage, adipose tissue
represents a site of plural activities involving secretion of a
wide gamma of active substances, a great proportion of them
portending inﬂammatory actions and/or highly regulated
by inﬂammation. By imposing a state of nutrient overload,
obesity signiﬁcantly boosts inﬂammation in adipose tissue
and other metabolic organs, with consequent impairment of
insulin signaling and abnormalities in glucose metabolism.
Progressive understanding of all inﬂammatory mechanisms
operating in obesity is mandatory for further therapeutic
advances.
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